ENTERA BIO LTD. Cost Of Sales
ENTERA BIO LTD. (ENTX) reported Cost Of Sales of $63.00 thousand for the 3-month period ending 2021-06-30, per its 6-K filed 2021-08-16.
Discontinued › Expense Statement
ifrs-full:CostOfSales · last filed 2021-08-16
- ENTERA BIO LTD. cost of sales for the quarter ending 2021-06-30 was $63.00K, a 103.23% increase year-over-year.
- ENTERA BIO LTD. cost of sales for the quarter ending 2020-06-30 was $31.00K, a 50.00% decline year-over-year.
- ENTERA BIO LTD. cost of sales for the quarter ending 2019-06-30 was $62.00K.
| Period end | Cost Of Sales 3 month | Cost Of Sales 6 month | Cost Of Sales 12 month |
|---|---|---|---|
| 2021-06-30 | $63.00K 6-K · filed 2021-08-16 | $121.00K 6-K · filed 2021-08-16 | |
| 2020-12-31 | $209.00K 20-F · filed 2021-03-18 | ||
| 2020-06-30 | $31.00K 6-K · filed 2021-08-16 | $73.00K 6-K · filed 2021-08-16 | |
| 2019-12-31 | $210.00K 20-F · filed 2021-03-18 | ||
| 2019-06-30 | $62.00K 6-K · filed 2020-08-20 | $62.00K 6-K · filed 2020-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |